Abstract
Background
This systematic review and meta-analysis aimed at investigate the role of locally delivered host-modulators in combination with step 2 of periodontal therapy in reducing probing pocket depth, improving clinical attachment level and reducing bone defect depth in intra-bony defects.
Highlight
RCT with at least 6 months follow-up were included in this study. Risk of bias assessment was performed with Cochrane collaboration tool and Grade GRADEpro. In addition, meta-analysis and trial sequential analysis were used to aggregate the available evidence. 22 studies met the inclusion criteria and were included in this systematic review. At 6 months locally delivered host-modulators significantly improved PD and CAL and bone defect depth.
Conclusion
Considering the emerging role of host-inflammatory response in the treatment of periodontitis, several studies are exploring the role of locally delivered host modulators as an adjunct to step 2 of periodontal therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: framework and proposal of a new classification and case definition. J Periodontol. 2018;89:S159–S72.
Haffajee AD, Socransky SS. Microbial etiological agents of destructive periodontal diseases. Periodontol 2000. 1994;5:78–111.
Papapanou PN, Wennstrom JL. The angular bony defect as indicator of further alveolar bone loss. J Clin Periodontol. 1991;18:317–22.
Umeda M, Takeuchi Y, Noguchi K, Huang Y, Koshy G, Ishikawa I. Effects of nonsurgical periodontal therapy on the microbiota. Periodontol 2000. 2004;36:98–120.
Cortellini P, Tonetti MS. Focus on intrabony defects: guided tissue regeneration. Periodontol 2000. 2000;22:104–32.
Van Dyke TE. Pro-resolving mediators in the regulation of periodontal disease. Mol Aspects Med. 2017;58:21–36.
Greenstein G, Polson A. The role of local drug delivery in the management of periodontal diseases: a comprehensive review. J Periodontol. 1998;69:507–20.
Goodson JM, Hogan PE, Dunham SL. Clinical responses following periodontal treatment by local drug delivery. J Periodontol. 1985;56:81–7.
Higgins JP, Thomas, J, Chandler, J, Cumpston, M, Li, T, Page, MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. 2. Wiley-Blackwell. 2020.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Morgan RL, Whaley P, Thayer KA, Schunemann HJ. Identifying the PECO: a framework for formulating good questions to explore the association of environmental and other exposures with health outcomes. Environ Int. 2018;121:1027–31.
Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol. 2002;31:140–9.
Lesaffre E, Garcia Zattera MJ, Redmond C, Huber H, Needleman I. Dentistry ISo. Reported methodological quality of split-mouth studies. J Clin Periodontol. 2007;34:756–61.
Lesaffre E, Philstrom B, Needleman I, Worthington H. The design and analysis of split-mouth studies: what statisticians and clinicians should know. Stat Med. 2009;28:3470–82.
Guida L, Bressan E, Cecoro G, Volpe AD, Del Fabbro M, Annunziata M. Short versus longer implants in sites without the need for bone augmentation: a systematic review and meta-analysis of randomized controlled trials. Materials (Basel). 2022;15:3138.
Patil KS, Mahajani M, Choudhary SH, Aldhuwayhi SD, Thakare A, Mustafa MZ. Efficacy of 1.5% metformin gel as an adjuvant to scaling, root planing, and curettage for the treatment of infrabony defects in chronic periodontitis patients. Contemp Clin Dent. 2022;13:18–23.
Shirke PY, Kolte AP, Kolte RA, Bawanakar PV. Evaluation of the clinical efficacy of 1.2% atorvastatin in the treatment of periodontal intraosseous defects by CBCT: A randomized controlled clinical trial. J Dent Res Dent Clin Dent Prospects. 2019;13:183–91.
Gonde NP, Rathod SR, Kolte AP. Comparative evaluation of 1% melatonin gel in the treatment of intrabony defect: a randomized controlled clinical trial. J Periodontol. 2022;93:1878–88.
Gupta A, Govila V, Pant VA, Gupta R, Verma UP, Ahmad H, et al. A randomized controlled clinical trial evaluating the efficacy of zoledronate gel as a local drug delivery system in the treatment of chronic periodontitis: A clinical and radiological correlation. Natl J Maxillofac Surg. 2018;9:22–32.
Kurian IG, Dileep P, Ipshita S, Pradeep AR. Comparative evaluation of subgingivally-delivered 1% metformin and Aloe vera gel in the treatment of intrabony defects in chronic periodontitis patients: a randomized, controlled clinical trial. J Investig Clin Dent. 2018;9:e12324.
Pankaj D, Sahu I, Kurian IG, Pradeep AR. Comparative evaluation of subgingivally delivered 1.2% rosuvastatin and 1% metformin gel in treatment of intrabony defects in chronic periodontitis: a randomized controlled clinical trial. J Periodontol. 2018;89:1318–25.
Kanoriya D, Singhal S, Garg V, Pradeep AR, Garg S, Kumar A Clinical efficacy of subgingivally-delivered 0.75% boric acid gel as an adjunct to mechanotherapy in chronic periodontitis: a randomized, controlled clinical trial. J Investig Clin Dent. 2018;9:e12271. https://doi.org/10.1111/jicd.12271.
Pradeep AR, Patnaik K, Nagpal K, Karvekar S, Ramamurthy BL, Naik SB, et al. Efficacy of locally-delivered 1% metformin gel in the treatment of intrabony defects in patients with chronic periodontitis: a randomized, controlled clinical trial. J Investig Clin Dent. 2016;7:239–45.
Priyanka N, Abhilash A, Saquib S, Malgaonkar N, Kudyar N, Gupta A, et al. Clinical efficacy of subgingivally delivered 1.2 mg simvastatin in the treatment of patients with aggressive periodontitis: a randomized controlled clinical trial. Int J Periodontics Restorative Dent. 2017;37:e135–e41.
Martande SK M, Pradeep AR, Singh SP, Suke DK. Comparative evaluation of efficacy of subgingivally delivered 1.2% Atorvastatin and 1.2% Simvastatin in the treatment of intrabony defects in chronic periodontitis: a randomized controlled trial. J Dental Res Dental Clinics Dental Prospects. 2016;11:18–25.
Sharma A, Raman A, Pradeep AR. Role of 1% alendronate gel as adjunct to mechanical therapy in the treatment of chronic periodontitis among smokers. J Appl Oral Sci. 2017;25:243–9.
Pradeep AR, Kanoriya D, Singhal S, Garg V, Manohar B, Chatterjee A Comparative evaluation of subgingivally delivered 1% alendronate versus 1.2% atorvastatin gel in treatment of chronic periodontitis: a randomized placebo-controlled clinical trial. J Investig Clin Dent.2017;8. https://doi.org/10.1111/jicd.12215.
Kumari M, Martande SS, Pradeep AR Subgingivally delivered 1.2% atorvastatin in the treatment of chronic periodontitis among smokers: a randomized, controlled clinical trial. J Investig Clin Dent. 2017;8. https://doi.org/10.1111/jicd.12213.
Pradeep AR, Garg V, Kanoriya D, Singhal S. 1.2% rosuvastatin versus 1.2% atorvastatin gel local drug delivery and redelivery in treatment of intrabony defects in chronic periodontitis: a randomized placebo-controlled clinical trial. J Periodontol. 2016;87:756–62.
Pradeep AR, Karvekar S, Nagpal K, Patnaik K, Guruprasad CN, Kumaraswamy KM. Efficacy of locally delivered 1.2% rosuvastatin gel to non-surgical treatment of patients with chronic periodontitis: a randomized, placebo-controlled clinical trial. J Periodontol. 2015;86:738–45.
Rao NS, Pradeep AR, Bajaj P, Kumari M, Naik SB. Simvastatin local drug delivery in smokers with chronic periodontitis: a randomized controlled clinical trial. Aust Dent J. 2013;58:156–62.
Rao NS, Pradeep AR, Kumari M, Naik SB. Locally delivered 1% metformin gel in the treatment of smokers with chronic periodontitis: a randomized controlled clinical trial. J Periodontol. 2013;84:1165–71.
Pradeep AR, Kumari M, Rao NS, Martande SS, Naik SB. Clinical efficacy of subgingivally delivered 1.2% atorvastatin in chronic periodontitis: a randomized controlled clinical trial. J Periodontol. 2013;84:871–9.
Pradeep AR, Rao NS, Naik SB, Kumari M. Efficacy of varying concentrations of subgingivally delivered metformin in the treatment of chronic periodontitis: a randomized controlled clinical trial. J Periodontol. 2013;84:212–20.
Sharma A, Pradeep AR. Clinical efficacy of 1% alendronate gel as a local drug delivery system in the treatment of chronic periodontitis: a randomized, controlled clinical trial. J Periodontol. 2012;83:11–8.
Sharma A, Pradeep AR. Clinical efficacy of 1% alendronate gel in adjunct to mechanotherapy in the treatment of aggressive periodontitis: a randomized controlled clinical trial. J Periodontol. 2012;83:19–26.
Pradeep AR, Thorat MS. Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: a randomized clinical trial. J Periodontol. 2010;81:214–22.
Pradeep AR, Patnaik K, Nagpal K, Karvekar S, Guruprasad CN, Kumaraswamy KM. Efficacy of 1% metformin gel in patients with moderate and severe chronic periodontitis: a randomized controlled clinical trial. J Periodontol. 2017;88:1023–9.
Pradeep AR, Nagpal K, Karvekar S, Patnaik K, Naik SB, Guruprasad CN. Platelet-rich fibrin with 1% metformin for the treatment of intrabony defects in chronic periodontitis: a randomized controlled clinical trial. J Periodontol. 2015;86:729–37.
Hunninghake DB. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy. Am J Med. 1998;104:9S–13S.
Garrett IR, Gutierrez G, Mundy GR. Statins and bone formation. Curr Pharm Des. 2001;7:715–36.
Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res. 2008;5:157–67.
Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122:253–70.
Fleisch H. Bisphosphonates: mechanisms of action and clinical use in osteoporosis-an update. Horm Metab Res. 1997;29:145–50.
Acknowledgements
This review utilised only publicly available and published data thus formal ethical approval was not required.
Author information
Authors and Affiliations
Contributions
CA conceptualized the study; CA and PM elaborated the methods of the study; CA, DR and PM extracted and analysed the data; CA and KZ wrote the first draft of the manuscript; CA, LL and PM revised and prepared the final version for submission. All authors have read and agreed to the published version of the manuscript. All authors have read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Arena, C., Mariani, P., Russo, D. et al. Adjunctive use of locally delivered host-modulators in intra-bony defects as part of step 2 periodontal therapy: systematic review, meta-analysis and trial sequential analysis. Evid Based Dent 24, 91–92 (2023). https://doi.org/10.1038/s41432-023-00877-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41432-023-00877-5